Table 1. Baseline characteristics of study patients.
| Variables | Primary cohort No. (%) | Validation cohort No. (%) | P-value |
|---|---|---|---|
| No. of patients | 984 | 492 | |
| Age (years) | 58(48,67) | 58(48,67) | 0.767 |
| T stage | 0.620 | ||
| T1 | 262(26.6) | 132(26.8) | |
| T2 | 570(57.9) | 295(59.9) | |
| T3 | 123(12.5) | 50(10.2) | |
| T4 | 29(3.0) | 15(3.1) | |
| N stage | 0.987 | ||
| N0 | 453(46.0) | 222(45.1) | |
| N1 | 341(34.7) | 169(34.4) | |
| N2 | 107(10.9) | 56(11.4) | |
| N3 | 72(7.3) | 39(7.9) | |
| Unknown | 11(1.1) | 6(1.2) | |
| TNM stage | 0.980 | ||
| I | 170(17.3) | 82(16.7) | |
| II | 569(57.8) | 284(57.7) | |
| III | 226(23.0) | 117(23.8) | |
| IV | 19(1.9) | 9(1.8) | |
| ER status | 0.925 | ||
| Negative | 206(20.9) | 101(20.5) | |
| Positive | 738(75.0) | 369(75.0) | |
| Unknown | 40(4.1) | 22(4.5) | |
| PR status | 0.878 | ||
| Negative | 262(26.6) | 137(27.9) | |
| Positive | 598(60.8) | 295(59.9) | |
| Unknown | 124(12.6) | 60(12.2) | |
| HER2 status | 0.980 | ||
| Negative | 679(69.0) | 337(68.5) | |
| Positive | 152(15.5) | 77(15.6) | |
| Unknown | 153(15.5) | 78(15.9) |
Abbreviations: TNM, tumor-node-metastasis; ER, estrogen receptor; PR, progesterone receptor; HER2, human epithelial growth factor receptor 2.